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Abstract
Aims—The purpose of this study was to describe how washout period duration affects the size 
and accuracy of retrospective incident user cohorts.
Materials & methods—MarketScan commercial claims data from 2007 to 2010 were used and 
included adults with an antihyperlipidemic, antidiabetic or antidepressant claim in 2010. Incident 
user cohorts using 3-, 6-, 12-, 24- and 36-month washouts were created and changes in sample size 
and incident user misclassification were described.
Results & conclusion—The 6- and 12-month washouts excluded 75 and 85% of the samples, 
respectively. Half of subjects in the 6-month washout cohorts were actually prevalent users, and 
the 12-month washout period resulted in 30% misclassified. Using common washout periods of 6–
12 months may insufficiently address prevalent user bias in large commercial claims databases.
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In recent decades, the fields of pharmaceutical outcomes, pharmacoepidemiology, 
pharmacovigilance and comparative effectiveness research have increasingly relied on 
observational cohort study methodologies employed in large administrative claims data sets. 
[1,2] The primary challenge of these studies lies in addressing selection bias stemming from 
the lack of randomization of study subjects to treatment [3]. Prevalent user bias is one 
common form of selection bias and confounding that occurs when observational cohort 
studies include subjects with prior exposure to the medication therapy being investigated 
[4,5]. Prevalent user bias typically manifests through inflated estimates of medication 
benefits and safety because studies including prevalent users in their analyses have 
disproportionately selected for patients with demonstrated success on therapy [6–8]. For 
example, a recent meta-analysis of observational cohort studies investigating the association 
of statin use and mortality found that the studies designed to mitigate prevalent user bias 
estimated a 23% mortality reduction, whereas the studies that failed to address prevalent 
user bias reported a 46% mortality reduction attributable to statin use, inappropriately 
doubling the true estimates of benefit [6].
Researchers reduce prevalent user bias by restricting samples to new, or incident, users of 
study medications [9]. This is achieved through identifying and excluding patients that 
exhibit previous use of the study medication in claims data during a pre-index date ‘washout 
period’ [4,5]. Selection of the washout period duration in an incident user design presents 
clear trade-offs for observational researchers. A longer washout period assures greater 
internal validity due to more thorough assessment of prevalent use [10], but these longer 
washout periods reduce generalizability and estimate precision, through the loss of sample 
size with increasing restrictions [11]. Although certain factors, such as the length of time a 
drug has been on the market and data availability, can help inform the washout duration 
decision, a washout period legacy standard of 6–12 months has developed among 
observational researchers [11,12]. However, little evidence exists to explicitly substantiate 
the use of 6–12-month washout periods in claims-based incident user studies or to inform 
appropriate washout period selection based for a specific research question [13,14].
The purpose of this study was to describe the effect of implementing washout period criteria 
of increasing duration on sample size and accuracy of retrospective, incident user cohorts 
across three condition-centric groups: antihyperlipidemic, antidiabetic and antidepressant 
users. The implications of washout period duration are evaluated in these three clinical 
areas, as they are highly prevalent medically-managed conditions with varying clinical 
courses and presentations [15–19].
Materials & methods
Data source
Truven Health Analytics MarketScan Commercial Claims and Encounters data from 2007 to 
2010 were used. MarketScan captures health insurance enrollment information, as well as 
inpatient, outpatient and pharmacy utilization data for roughly 20 million private health 
insurance beneficiaries annually from approximately 100 commercial payers [20].
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Adults aged 18–64 years with at least one outpatient prescription claim in 2010 for drugs 
approved in the USA to treat hyperlipidemia, diabetes or depression were included. 
Antihyperlipidemic medications included HMG-CoA reductase inhibitors (statins), 
ezetimibe, bile acid sequestrants, fibric acid derivatives, prescription-only niacin 
preparations and prescription-only omega-3-acid ethyl esters [17,21]. Antidiabetic 
medications included metformin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 
inhibitors, meglitinides, alpha-glucosidase inhibitors, and injectable insulin and incretin 
mimetic formulations [16,22]. Antidepressant medications included selective serotonin 
reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclics, bupropion, 
maprotiline, monoamine oxidase inhibitors and serotonin antagonist reuptake inhibitors [23]. 
Combination products with at least one of the listed study medications were also included.
Study cohort definition
The index fill was the first fill date for a qualifying medication in one of the three study 
cohorts in calendar year 2010. Individuals could be included in multiple disease-state-centric 
cohorts and the index date was allowed to vary between cohorts for such individuals. For 
each of the three cohorts, a series of five washout periods of increasing length – 3, 6, 12, 24 
and 36 months – was used to assess prevalent use and create increasingly restrictive incident 
user cohorts (Figure 1). A treatment-naive definition of incident use was used, in which 
having at least one prescription claim for any cohort-specific study medication in the 
washout period, regardless of whether or not it matched the index drug or index drug class, 
constituted prevalent use. For example, an antihyperlipidemic user whose index medication 
was simvastatin would be considered a prevalent user if, in the given washout period, they 
had a claim for simvastatin, another statin or any other antihyperlipidemic agent. This is the 
strictest definition of prevalent use and is commonly employed in comparative effectiveness 
studies of pharmacotherapies, in which subjects are required to have never been treated for 
the condition under study to ensure similar baseline risks of the study outcome across 
groups. Inclusion in each of the incident user cohorts also required continuous insurance 
enrollment for the duration of the given washout period, defined by having a gap in 
coverage no greater than 7 days. This is necessary in incident user designs to ensure 
complete assessment of a subject's medication use for the entire washout period. A 
sensitivity analysis allowing a 30-day gap in insurance coverage was conducted; the results 
were unchanged, so the findings are presented using a 7-day coverage gap.
Analysis
Changes in sample size were described for each condition-centric cohort as the increasingly 
restrictive washout criteria were applied. The singular effect of the continuous prior 
enrollment requirement on sample size was also examined to understand its impact 
separately from incident use criteria. Last, for each of the hyperlipidemia, diabetes and 
depression cohorts the rate of incident user misclassification across washout durations was 
described. To assess this, we restricted our analysis to subjects with a full 36 months of 
continuous insurance enrollment prior to their index fill date. Among these individuals, 
subjects meeting the 36-month washout criteria were considered true incident users. 
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Washout periods of 3, 6, 12 and 24 months were applied to those with 36 months of 
continuous enrollment. Additional subjects included in incident user cohorts created from 
shorter washout periods beyond those included in the true incident user cohort were 
considered misclassified due to the washout period's inability to identify known prevalent 
use between 36 months pre-index date and the start of the washout period. SAS 9.3 (Cary, 
NC) was used for all analyses. Approval for this study was obtained from the University of 
North Carolina at Chapel Hill Institutional Review Board.
Results
We identified 3,477,743 antihyperlipidemic, 1,455,651 antidiabetic, and 3,468,137 
antidepressant users with an index fill in calendar year 2010. Sample size loss in each 
disease-state cohort due to continuous enrollment and the washout period criteria, is reported 
in Table 1.
Requiring 3 months of continuous insurance enrollment prior to the index fill date excluded 
roughly 25% of subjects with an index medication fill across the three disease states, with 6 
and 12 months of continuous enrollment excluding around 30 and 35% of subjects, 
respectively (Table 1). The antidepressant user cohort was slightly more susceptible to 
sample loss due to continuous enrollment requirements; 71.2% of the original antidepressant 
user cohort was excluded with a 36-month continuous enrollment requirement compared 
with 65.6 and 65.7% for antihyperlipidemic and antidiabetic users, respectively.
Applying a 3-month washout period, in addition to the continuous enrollment requirement, 
resulted in loss of 54.1, 60.5 and 56.1% of subjects with any antihyperlipidemic, antidiabetic 
and antidepressant use in 2010, respectively. The legacy standard washout periods of 6 and 
12 months created incident user cohorts comprised only 22–27% and 13–17% of original 
subjects with an index antihyperlipidemic, antidiabetic and antidepressant prescription fill, 
respectively. Only 5% of subjects in each original cohort met the incident user criteria based 
on the most restrictive washout period of 36 months.
The observed changes in sample size across the 3, 6, 12, 24 and 36-month look-back periods 
are visualized in Figure 2A–C, which depict the relative impact of the continuous insurance 
enrollment requirement on sample size loss for each drug class of interest. A lack of 
continuous insurance enrollment was the cause of exclusion for roughly 40% of those 
excluded from incident user cohorts based on 3, 6 and 12-month washout periods. At longer 
washout periods of 24 and 36 months, 53 and 69% of the observed sample loss was due to 
the continuous enrollment requirement, respectively. The effect of continuous enrollment 
requirement was slightly greater in the antidepressant cohort. Over 45% of those excluded 
based on the 3- to 12-month washout periods were excluded due to insurance coverage gaps, 
as opposed to the incident use criteria. Of all subjects excluded by the 24 and 36-month 
washout periods, nearly two-thirds and three-quarters, respectively, were attributed to failing 
to meet the continuous enrollment requirement.
Figure 3 depicts the extent of incident user misclassification across washout period durations 
among the 1,195,528 antihyperlipidemic, 474,092 antidiabetic and 997,962 antidepressant 
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users with 36 months of continuous enrollment prior to their index fill. In each disease state, 
misclassification of incident users increased steadily as washout periods decreased. When 
using a 12-month washout period, 25.5% of the antidiabetic and nearly one-third of the 
antihyperlipidemic and antidepressant users identified as incident users actually had 
prevalent use at some point during the entire 36-month pre-index period. Decreasing the 
washout period to 6 months resulted in an incident user cohort in which half of the subjects 
had prevalent use while 67–77% of those identified as incident users using a 3-month 
washout period were misclassified.
Out of the three disease states, antihyperlipidemic users were most likely to be misclassified 
in the 3-, 6- and 12-month washouts, and antidepressant incident users experienced the 
greatest misclassification at the 24-month washout period. Antidiabetic users were generally 
least likely to be misclassified as incident users across washout periods. However, 
misclassification trends were comparable across disease states.
Discussion
The effect of using washout periods of increasing duration on the size and accuracy of 
antihyperlipidemic, antidiabetic and antidepressant incident user cohorts in a large 
administrative claims database was described. In general, the observed trends in sample size 
loss and incident user misclassification across washout periods were comparable across 
disease states with varying clinical courses and presentations.
Substantial and rapid loss of sample size was found with commonly used continuous 
enrollment and washout period criteria of 6 and 12 months, which resulted in exclusion of 
about 75 and 85% of initially qualifying drug users, respectively. Continuous enrollment 
requirements were responsible for about 40–45% of observed sample size loss in the 3- to 
12-month washout cohorts and over half to two-thirds of the sample size loss in the most 
restrictive washout cohorts.
Study findings related to incident user misclassification highlight serious concerns over the 
ability of 6- and 12-month washout periods to accurately identify incident users. Not only 
did the 6-month continuous enrollment and washout period result in a loss of three-quarters 
of the original sample across the disease states, but one out of every two subjects included in 
the incident user cohorts actually had prior use at some point between 6 and 36 months 
preceding the index fill. Extending the washout period to 12 months still resulted in the 
creation of incident user cohorts in which one-third of included subjects were incorrectly 
classified as incident users, while losing an additional 10% of the original sample. This 
suggests that observational incident user studies employing commonly used washout periods 
of 6–12 months likely suffer from notable residual prevalent user bias.
Incident user study designs require careful consideration of the consequences of the washout 
period duration selection. Shorter washout periods of 3–6 months may be necessary in the 
context of a priori concerns about sample size, limited data availability or when 
investigating newly-approved therapies. However, in light of these results showing that 
washout periods of 12 months or less may be insufficient for accurately identifying 
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prevalent users, researchers implementing incident user designs should consider employing 
washout periods greater than 12 months to better ensure their cohorts contain treatment-
naive patients. Doing so could drastically reduce the threat of prevalent user bias while still 
allowing for adequately powered analyses, especially in studies involving very large data 
sets and/or highly prevalent pharmacotherapies. For example, extending the washout period 
in our antihyperlipidemic cohort from 12 to 24 months resulted in excluding only an 
additional 5% of the original sample of 3.5 million users, while reducing incident user 
misclassification from 33% to a little over 10%. At a minimum, researchers should conduct 
sensitivity analyses using varied washout period durations to assess the robustness of their 
study estimates in the face of potential residual prevalent user bias. While the goals of the 
study will dictate the relative importance of using longer washout periods, studies that 
require treatment naive patients may only be internally valid if restricted to the small sample 
with long washout periods [24,25]. Given the relative importance of internal validity over 
generalizability, the loss in sample is a reasonable trade-off.
Findings from our study should be interpreted in light of key limitations. First, a treatment-
naive definition of incident use was employed, in which a subject was deemed a prevalent 
user if they had filled a prescription for any medication indicated for the specific disease 
state in question. This approach may not be appropriate for all research questions; for 
example, in an observational cohort study investigating a drug-classspecific adverse effect, it 
would likely be more appropriate to define prevalent use as any prior exposure solely to 
medications in that specific drug class. Similarly, it may be appropriate to include 
individuals who had distant prior, short-term use of a drug depending on the goals of the 
study. Second, selection of an exposed cohort was the focus of this study, rather than 
selection of controls. It is possible that there may be differential detection of prevalent use 
among selected treatment and control groups for comparative effectiveness studies, which 
may introduce bias. Last, this study was conducted among privately insured adults. The 
findings may not generalize to observational incident user studies conducted in other patient 
populations, such as Medicaid patients, who are known to experience more frequent gaps in 
insurance enrollment [26].
Conclusion
The effect of washout period duration on the size and accuracy of incident user cohorts in a 
large commercial insurance claims data set was examined. The findings emphasize the need 
for observational researchers to recognize that commonly used 6- to 12-month washout 
periods may insufficiently control for prevalent user bias. Researchers employing incident 
user study designs should carefully consider the duration of their washout period, utilize a 
washout period greater than 12 months when possible, and at the very least, conduct 
sensitivity analyses around their selected washout period to examine its influence on the 
specific population and outcomes being studied. There is a clear need to better understand 
the effects of incident use criteria on the results and generalizability of observational 
incident user studies in large claims data sets, especially considering the increasing reliance 
on these study methodologies to contribute to evidence-based clinical and regulatory 
decision-making.
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The role of observational research methods in large data sets, including incident user study 
designs, will continue to expand in the field of comparative effectiveness research of 
pharmacotherapies. During this time, researchers will continue to explore and employ 
rigorous research design and analytic strategies that improve the control of selection bias. 
This will be necessary not only to ensure that estimates of association between medications 
and outcomes reflect the truth to the greatest extent possible, but also to foster a strong sense 
of legitimacy in the contributions of observational comparative effectiveness research to the 
clinical evidence-base among key policy, provider, payer and patient stakeholders.
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• Observational comparative effectiveness research of pharmacotherapies often 
requires the incident user design, which reduces bias through the use of washout 
periods that identify and exclude subjects with prior use of the study medication.
• Researchers typically choose a 6- or 12-month washout period, despite limited 
evidence available to inform appropriate washout selection.
• The purpose of this study was to describe the effect of washout periods of 
increasing duration on sample size and accurate identification of incident users 
in a large commercial claims database.
Materials & methods
• MarketScan commercial claims data for years 2007–10 were used.
• Adults with a prescription claim for an antihyperlipidemic, antidiabetic, and/or 
antidepressant in 2010 were included, and a series of treatment-naive incident 
user cohorts within each disease state was created using washout periods of 3, 6, 
12, 24 and 36 months.
• Sample size loss across washout periods was described, as well as the singular 
effect of requiring subjects to have continuous insurance enrollment during the 
look-back period.
• The prevalence of misclassification in incident user cohorts across washout 
period durations was also described, by reporting the percentage of subjects that 
had prior exposure to a cohort medication preceding a given washout period.
Results
• Sample size dropped rapidly as washout periods increased, with roughly 85% of 
subjects excluded with a 12-month washout period.
• Lapses in continuous insurance enrollment in the data set were responsible for 
40% of the observed sample loss in washout periods of a year or less.
• Half of subjects identified as incident users with a 6-month washout period 
actually had a prior claim for a drug indicated for that condition, and 30% of 
subjects included in the 12-month washout incident user cohort were 
misclassified.
Discussion & conclusion
• Commonly used washout periods of 6–12 months may insufficiently control for 
prevalent user bias.
• Observational researchers employing an incident user design should consider 
using washout periods longer than 12 months when appropriate and possible.
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• At minimum, sensitivity analyses around washout period duration should be 
conducted in incident user designs to assess the robustness of study estimates in 
the face of possible residual prevalent user bias.
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Figure 1. Diagram depicting the creation of increasingly restrictive incident user cohorts using 
varied washout period durations in a single diseasestate-centric cohort
Figure 1 visualizes how the incident user cohorts were created with five washout periods of 
increasing duration anchored by the index prescription fill in 2010.
Roberts et al. Page 11













Figure 2. Incident user cohort sample size loss across washout periods, by disease state
This figure depicts the proportion of patients with an index fill in 2010 meeting the 
continuous enrollment and continuous enrollment plus washout criteria across look-back 
periods of increasing duration. Panels (A), (B), and (C) represent incident user cohort size 
changes across look-back periods for antihyperlipidemic, antidiabetic, and antidepressant 
user cohorts, respectively. Note: There were a total of 3,477,753 antihyperlipidemic, 
1,445,651 antidiabetic and 3,468,137 antidepressant users aged 18–64 years in calendar year 
2010.
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Figure 3. Misclassification of subjects as new users with increasingly restrictive washout periods 
among subjects with 36 months of continuous enrollment
The figure depicts that as the pre-index washout period duration decreases, the proportion of 
the incident user cohort comprised of subjects with prevalent use who were misclassified as 
incident users, increases steadily. Note: A total of 1,195,528, 474,092 and 997,962 study 
subjects had 36 months of continuous enrollment prior to the index fill for the 
hyperlipidemia, diabetes and depression cohorts, respectively. Study subjects meeting the 
36-month washout period criterion were considered true incident users. Reported numeric 
values represent percentage of those included in the incident user cohort that were actually 
prevalent users.
Roberts et al. Page 13












































































































































































































































































































































































































































































































































































































































































J Comp Eff Res. Author manuscript; available in PMC 2015 November 01.
